2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma

The main objective of this trial was to determine the value of 2 courses of cisplatin concurrent chemotherapy in postoperative adjuvant radiotherapy for high-risk head and neck squamous cell carcinoma.

Trial Details

NCT ID
NCT06492460
Phase
PHASE3
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Drug:Cisplatin
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guilin, Guangxi, China|25.28022,110.29639
  • Changsha, Hunan, China|28.19874,112.97087
  • Changsha, Hunan, China|28.19874,112.97087
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • A. The pathological type is head and neck squamous cell carcinoma
  • Stages III and IV
  • B. Radical surgery has been performed with high risk factors (one of below)
  • extracapsular invasion of cervical metastatic lymph nodes

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →